Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -39.10%
Price change 2019 → 2020: -14.15%
Price change 2020 → 2021: -0.67%
Price change 2021 → 2022: -76.43%
Price change 2022 → 2023: -10.72%
Price change 2023 → 2024: -93.44%
Price change 2024 → 2025: -92.93%
Price change 2025 → 2026: -36.16%
Price change 2026 (year to date): -40.12%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.03
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.14
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 49.06% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="OGEN" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Oragenics, Inc. | – | 0.03 | – | 🔒 |
| WORK Medical Technology Group Ltd. | – | 0.35 | −28.4 % | – |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
| CompuMed, Inc. | – | 0.23 | +10.2 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Oragenics, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2010 | 1.3 m | -7.8 m | -596.3 % | n/a |
| 2011 | 1.4 m | -7.7 m | -531.8 % | +10.3 % |
| 2012 | 1.3 m | -13.1 m | -982.7 % | -7.8 % |
| 2013 | 1.0 m | -16.1 m | -1,557.1 % | -22.5 % |
| 2014 | 939,926 | -5.8 m | -616.0 % | -8.9 % |
| 2015 | 1.2 m | -11.7 m | -995.8 % | +25.1 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Oragenics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | n/a | 11.4 m | 3.5 m | 864,840 | 8.4 m |
| Total Debt | 797,206 | 624,526 | 322,514 | 328,528 | 227,348 |
| Net Debt | -26.5 m | -10.8 m | -3.2 m | -536,312 | -4.2 m |
| Equity | 26.5 m | 13.0 m | 3.2 m | -211,885 | 8.3 m |
| Total assets | n/a | 14.8 m | 5.0 m | 1.5 m | 10.1 m |
| Operating cash flow | -13.5 m | -15.2 m | -7.3 m | -8.6 m | -9.2 m |
| Investments (capex) | 43,876 | 127,519 | 1.0 m | 0 | 0 |
| Free cash-flow | -13.5 m | -15.4 m | -8.3 m | -8.6 m | -9.2 m |
| Share buybacks | 5.6 m | 0 | 0 | 0 | 0 |
| Dividends paid | 1.1 m | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Dividends and earnings
Oragenics, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 12/11/2026 | -0.58 | -90.00 | n/a |
| 13/08/2026 | -0.57 | -90.00 | n/a |
| 08/05/2026 | -0.51 | -90.00 | n/a |
| 26/02/2026 | -0.54 | -90.00 | n/a |
| 07/11/2025 | -1.96 | -144.00 | n/a |
| 13/11/2024 | -11.41 | -90.00 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 03/06/2025 | reverse split: 1 share for 30 |
| 23/01/2023 | reverse split: 1 share for 60 |
| 22/01/2018 | reverse split: 1 share for 10 |
| 28/09/2010 | reverse split: 1 share for 20 |
Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Oragenics, Inc.
What is the Oragenics, Inc. share price?
Latest recorded price: 0.201 USD on 13/11/2026, for a market cap of 906,903 USD.
What is the revenue of Oragenics, Inc.?
1.2 m USD for fiscal year 2015, with net income of -11.7 m USD (net margin -995.8 %).
Is Oragenics, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US6840236094).
How many employees does Oragenics, Inc. have?
3 full-time employees according to the latest published profile.
Who runs Oragenics, Inc.?
Janet Huffman is the company's chief executive.